What changed 10-Q

Item 5. Other Information

2023-08-01 compared with 2023-05-02 · 10 added, 0 removed, 35 unchanged (22% of the section changed)

Other Information

Securities Trading Plans of Directors and Executive Officers

During the three months ended June 30, 2023, none of our directors or executive officers adopted or terminated any contract , instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.

6 unchanged sentences

Warrant issued to HCP BTC, LLC for the purchase of shares of common stock.

Rigel Pharmaceuticals, Inc.

2018 Equity Incentive Plan, as amended.

Rigel Pharmaceuticals, Inc.

Inducement Plan, as amended.

Amendments 1, 2 and 3 to License and Transition Services Agreement with Forma Therapeutics, Inc.

Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.

9 unchanged sentences

Filed herewith

˄ Certain marked information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private and confidential.

* The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.

11 unchanged sentences

(Principal Executive Officer)

August 1, 2023

Chief Financial Officer

(Principal Financial Officer)

August 1, 2023

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.